Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes

Norman E Cameron, T M Gibson, M R Nangle, M A Cotter

Research output: Book/ReportBook

88 Citations (Scopus)

Abstract

Advanced glycation and lipoxidation end products (AGEs/ALEs) have been implicated in the pathogenesis of the major microvascular complications of diabetes mellitus: nephropathy, neuropathy, and retinopathy. This article reviews the evidence regarding the peripheral nerve and its vascular supply. Most investigations done to assess the role of AGEs/ALEs in animal models of diabetic neuropathy have used aminoguanidine as a prototypic inhibitor. Preventive or intervention experiments have shown treatment benefits for motor and sensory nerve conduction velocity, autonomic nitrergic neurotransmission, nerve morphometry, and nerve blood flow. The latter depends on improvements in nitric oxide-mediated endothelium-dependent vasodilation and is responsible for conduction velocity improvements. A mechanistic interpretation of aminoguanidine's action in terms of AGE/ALE inhibition is made problematic by the relative lack of specificity. However, other unrelated compounds, such as pyridoxamine and pyridoxamine analogues, have recently been shown to have beneficial effects similar to aminoguanidine, as well as to improve pain-related measures of thermal hyperalgesia and tactile allodynia. These data also stress the importance of redox metal ion-catalyzed AGE/ALE formation. A further approach is to decrease substrate availability by reducing the elevated levels of hexose and triose phosphates found in diabetes. Benfotiamine is a transketolase activator that directs these substrates to the pentose phosphate pathway, thus reducing tissue AGEs. A similar spectrum of improvements in nerve and vascular function were noted when using benfotiamine in diabetic rats. Taken together, the data provide strong support for an important role for AGEs/ALEs in the etiology of diabetic neuropathy.

Original languageEnglish
PublisherUnknown Publisher
Number of pages9
DOIs
Publication statusPublished - 2005

Keywords

  • diabetes
  • neuropathy
  • conduction velocity
  • advanced glycation end products
  • aminoguanidine
  • pyridoxamine
  • benfotiamine
  • blood flow
  • nitric oxide
  • endothelium
  • NITRIC-OXIDE SYNTHASE
  • PERIPHERAL-NERVE FUNCTION
  • 3 MAJOR PATHWAYS
  • HYPERGLYCEMIC DAMAGE
  • BLOOD-FLOW
  • STRUCTURAL ABNORMALITIES
  • AMINOGUANIDINE TREATMENT
  • ENDOTHELIAL-CELLS
  • ALDOSE REDUCTASE
  • RATS

Cite this

Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes. / Cameron, Norman E; Gibson, T M ; Nangle, M R ; Cotter, M A .

Unknown Publisher, 2005. 9 p.

Research output: Book/ReportBook

Cameron, Norman E ; Gibson, T M ; Nangle, M R ; Cotter, M A . / Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes. Unknown Publisher, 2005. 9 p.
@book{8585dd791eda48559bd1e9bbf4115508,
title = "Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes",
abstract = "Advanced glycation and lipoxidation end products (AGEs/ALEs) have been implicated in the pathogenesis of the major microvascular complications of diabetes mellitus: nephropathy, neuropathy, and retinopathy. This article reviews the evidence regarding the peripheral nerve and its vascular supply. Most investigations done to assess the role of AGEs/ALEs in animal models of diabetic neuropathy have used aminoguanidine as a prototypic inhibitor. Preventive or intervention experiments have shown treatment benefits for motor and sensory nerve conduction velocity, autonomic nitrergic neurotransmission, nerve morphometry, and nerve blood flow. The latter depends on improvements in nitric oxide-mediated endothelium-dependent vasodilation and is responsible for conduction velocity improvements. A mechanistic interpretation of aminoguanidine's action in terms of AGE/ALE inhibition is made problematic by the relative lack of specificity. However, other unrelated compounds, such as pyridoxamine and pyridoxamine analogues, have recently been shown to have beneficial effects similar to aminoguanidine, as well as to improve pain-related measures of thermal hyperalgesia and tactile allodynia. These data also stress the importance of redox metal ion-catalyzed AGE/ALE formation. A further approach is to decrease substrate availability by reducing the elevated levels of hexose and triose phosphates found in diabetes. Benfotiamine is a transketolase activator that directs these substrates to the pentose phosphate pathway, thus reducing tissue AGEs. A similar spectrum of improvements in nerve and vascular function were noted when using benfotiamine in diabetic rats. Taken together, the data provide strong support for an important role for AGEs/ALEs in the etiology of diabetic neuropathy.",
keywords = "diabetes, neuropathy, conduction velocity, advanced glycation end products, aminoguanidine, pyridoxamine, benfotiamine, blood flow, nitric oxide, endothelium, NITRIC-OXIDE SYNTHASE, PERIPHERAL-NERVE FUNCTION, 3 MAJOR PATHWAYS, HYPERGLYCEMIC DAMAGE, BLOOD-FLOW, STRUCTURAL ABNORMALITIES, AMINOGUANIDINE TREATMENT, ENDOTHELIAL-CELLS, ALDOSE REDUCTASE, RATS",
author = "Cameron, {Norman E} and Gibson, {T M} and Nangle, {M R} and Cotter, {M A}",
year = "2005",
doi = "10.1196/annals.1333.091",
language = "English",
publisher = "Unknown Publisher",

}

TY - BOOK

T1 - Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes

AU - Cameron, Norman E

AU - Gibson, T M

AU - Nangle, M R

AU - Cotter, M A

PY - 2005

Y1 - 2005

N2 - Advanced glycation and lipoxidation end products (AGEs/ALEs) have been implicated in the pathogenesis of the major microvascular complications of diabetes mellitus: nephropathy, neuropathy, and retinopathy. This article reviews the evidence regarding the peripheral nerve and its vascular supply. Most investigations done to assess the role of AGEs/ALEs in animal models of diabetic neuropathy have used aminoguanidine as a prototypic inhibitor. Preventive or intervention experiments have shown treatment benefits for motor and sensory nerve conduction velocity, autonomic nitrergic neurotransmission, nerve morphometry, and nerve blood flow. The latter depends on improvements in nitric oxide-mediated endothelium-dependent vasodilation and is responsible for conduction velocity improvements. A mechanistic interpretation of aminoguanidine's action in terms of AGE/ALE inhibition is made problematic by the relative lack of specificity. However, other unrelated compounds, such as pyridoxamine and pyridoxamine analogues, have recently been shown to have beneficial effects similar to aminoguanidine, as well as to improve pain-related measures of thermal hyperalgesia and tactile allodynia. These data also stress the importance of redox metal ion-catalyzed AGE/ALE formation. A further approach is to decrease substrate availability by reducing the elevated levels of hexose and triose phosphates found in diabetes. Benfotiamine is a transketolase activator that directs these substrates to the pentose phosphate pathway, thus reducing tissue AGEs. A similar spectrum of improvements in nerve and vascular function were noted when using benfotiamine in diabetic rats. Taken together, the data provide strong support for an important role for AGEs/ALEs in the etiology of diabetic neuropathy.

AB - Advanced glycation and lipoxidation end products (AGEs/ALEs) have been implicated in the pathogenesis of the major microvascular complications of diabetes mellitus: nephropathy, neuropathy, and retinopathy. This article reviews the evidence regarding the peripheral nerve and its vascular supply. Most investigations done to assess the role of AGEs/ALEs in animal models of diabetic neuropathy have used aminoguanidine as a prototypic inhibitor. Preventive or intervention experiments have shown treatment benefits for motor and sensory nerve conduction velocity, autonomic nitrergic neurotransmission, nerve morphometry, and nerve blood flow. The latter depends on improvements in nitric oxide-mediated endothelium-dependent vasodilation and is responsible for conduction velocity improvements. A mechanistic interpretation of aminoguanidine's action in terms of AGE/ALE inhibition is made problematic by the relative lack of specificity. However, other unrelated compounds, such as pyridoxamine and pyridoxamine analogues, have recently been shown to have beneficial effects similar to aminoguanidine, as well as to improve pain-related measures of thermal hyperalgesia and tactile allodynia. These data also stress the importance of redox metal ion-catalyzed AGE/ALE formation. A further approach is to decrease substrate availability by reducing the elevated levels of hexose and triose phosphates found in diabetes. Benfotiamine is a transketolase activator that directs these substrates to the pentose phosphate pathway, thus reducing tissue AGEs. A similar spectrum of improvements in nerve and vascular function were noted when using benfotiamine in diabetic rats. Taken together, the data provide strong support for an important role for AGEs/ALEs in the etiology of diabetic neuropathy.

KW - diabetes

KW - neuropathy

KW - conduction velocity

KW - advanced glycation end products

KW - aminoguanidine

KW - pyridoxamine

KW - benfotiamine

KW - blood flow

KW - nitric oxide

KW - endothelium

KW - NITRIC-OXIDE SYNTHASE

KW - PERIPHERAL-NERVE FUNCTION

KW - 3 MAJOR PATHWAYS

KW - HYPERGLYCEMIC DAMAGE

KW - BLOOD-FLOW

KW - STRUCTURAL ABNORMALITIES

KW - AMINOGUANIDINE TREATMENT

KW - ENDOTHELIAL-CELLS

KW - ALDOSE REDUCTASE

KW - RATS

U2 - 10.1196/annals.1333.091

DO - 10.1196/annals.1333.091

M3 - Book

BT - Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes

PB - Unknown Publisher

ER -